对话杨青博士：合作创新，助力生态圈可持续发展 | Bilingual

编者按：

作为全球医药健康产业的积极贡献者，药明康德致力于通过一体化CRDMO模式，助力全球医药创新，为客户、为行业、为患者创造价值。

今天，我们将目光投向欧洲。在这里，悠久的历史与蓬勃的创新活力交融，大型药企、新锐生物技术公司、权威研究机构云集，学术与产业的网络紧密交织，不断推动科学成果的转化，为患者带去希望。

但行业媒体BioXconomy指出，尽管研究创新在持续大量地涌现，欧洲生物技术领域目前依然面临资金和转化挑战。要让实验室里的突破真正成为最终问世的产品，对小型biotech公司来说尤为不易。

• 如何连接欧洲的区域创新中心，进一步合作释放创新的活力？

• 如何加速科学成果转化，帮助新兴biotech公司攻克资金挑战？

• CRDMO将如何助力共建可持续发展的医药创新生态圈？

最近，药明康德联席首席执行官杨青博士与BioXconomy对话，分享了自己对于行业发展和区域创新的洞见。

以下为对话实录，图片为编者添加。

BioXconomy: 您认为欧洲应当如何更好地发挥其科学创新优势？

杨青博士：欧洲拥有杰出的科研人才，但要将突破性发现转化为真正的商业化新药，历来是充满挑战的。虽然美国的资金更丰厚，但欧洲可以通过简化从基础研究到产品问世的转化流程，提升创新效率。药明康德的一体化CRDMO模式就能为这一过程提供切实的价值。

在美国，生物技术行业成功的一个关键因素就是创新者与合同研究组织（CRO）、合同开发与生产组织（CDMO）和合同生产组织（CMO）之间的广泛合作。通过体系化、模块化地合作，从早期引入一体化CRDMO服务，协同加速研发转化，到更强大的泛欧合作，相信欧洲也能涌现出更多更具可持续性和增长潜力的biotech公司。

BioXconomy: CRDMO平台具体有哪些优势？

杨青博士：CRDMO能够提供覆盖药物开发完整价值链的能力技术和规模设施，同时也承担着关键的教育职能：它能够支持学术机构孵化的公司和新兴企业跨越产业化的鸿沟，从容应对监管框架、行业质量标准和规模化流程。例如，一家大学孵化的公司要开发新型多肽疗法，可能会缺乏制剂工艺或GMP（药品生产质量管理规范）生产经验。通过与药明康德这样的CRDMO合作，既能获得高效的执行落地能力，又能吸收关键的产业化经验。

▲药明康德一体化CRDMO平台，端到端赋能新药从早期发现、开发到生产的全流程

BioXconomy: 您能否具体谈谈药明康德在欧洲的能力和战略？

杨青博士：欧洲是药明康德重要的战略发展区域。药明康德已在德国慕尼黑和瑞士库威设有运营基地，其中，慕尼黑基地专注于早期药物发现服务，提供X射线晶体结构解析、蛋白质科学、生物物理分析等定制化服务；库威基地则深耕制剂生产包装，致力于为后期临床和商业规模生产提供灵活高效的服务。

▲药明康德在欧洲持续建能力、扩规模，目前已在德国慕尼黑（上图）和瑞士库威（下图）设有两个运营基地

我们对欧洲的投入远不止于基地运营，还深度融入当地生态圈，包括支持可持续发展。例如，我们的瑞士基地采用地热能、太阳能与雨水回收系统等环保节能设施；我们在欧洲的发展注重培养当地管理团队与技术人员，为社区做出积极的贡献。

此外，我们与欧洲当地学术机构、风投机构和新兴生物技术公司积极合作，举办生态圈活动，建立战略合作伙伴关系。这种全方位的参与，使药明康德不仅仅是服务的提供商，更是欧洲生物医药创新发展的重要赋能者。

BioXconomy: 您刚刚提到了可持续发展。对您来说，一个可持续发展的生物医药创新生态圈意味着什么？

杨青博士：可持续的生物医药创新生态圈是一套强大的体系，在这里，创新研究能够从早期发现无缝推进到最终实现，biotech公司不再需要大量的早期投资，而能持续通过外部风投资金，构建多元、长期的管线，实现平稳发展。

各科学创新中心之间的合作深化也同样重要。不同地区各有所长，比如德国的慕尼黑擅长早期孵化，柏林更专注临床研究，海德堡则深耕基础科学——通过不同模块的合作，我们将连接这些生物技术中心，打造更有力的创新格局。这些合作还应在全球范围内拓展，比如连接美国、英国的产业集群，对各地最佳实践兼容并包，并持续开拓新的创新机遇。

美国马萨诸塞州的生物技术生态就是创新合作的典范，它成功整合了基础研究、资金、战略投资者、丰富的产业经验与能力规模，为欧洲的潜在成功路径提供了蓝图。

BioXconomy: 资金层面的挑战仍然不容忽视。风投公司如何改变其与（新药）开发合作伙伴的关系？这会带来哪些影响？

杨青博士：随着生物技术公司现在常常倾向后期退出，风投公司对产品商业化的机会和加速开发能力的期望也越来越高。投资者普遍寻求清晰、合规且高效的上市途径，这些因素将直接影响企业估值和退出潜力。

对于资金、资源有限的小型和新兴生物科技公司而言，与CRDMO合作的价值就尤其显著。

CRDMO始终围绕“质量、速度、成本”三大价值链，形成了强大的“飞轮”效应，能够为创新企业极致赋能，帮助客户将管线推进至关键的价值创造里程碑，以此提升估值，吸引投资，助力新药好药加速问世。

▲药明康德CRDMO平台围绕“质量、速度、成本”三大价值链，形成了强大的“飞轮”效应，能够为不同规模的创新企业极致赋能

Scaling success: How WuXi AppTec aims to catalyze Europe's biotech transformation

In this exclusive interview, co-CEO of WuXi AppTec Steve Yang shares insights on strengthening Europe's biotech ecosystem through strategic CRDMO partnerships.

Europe's biotech space is hampered by a notable disparity: an abundance of research innovation existing in parallel with capital and commercialization challenges. While the region excels in fundamental research and early discovery, European biotechs often struggle with the capital-intensive journey from laboratory breakthrough to market-ready product.

Yang spoke to BioXconomy about how Europe can better capitalize on its scientific strengths through integrated development partnerships and ecosystem collaboration. As WuXi AppTec expands its European footprint with specialized facilities in Germany and Switzerland, Yang provided insights on connecting regional innovation hubs, navigating funding challenges, and building sustainable growth models that could potentially transform Europe's scientific know-how into commercial leadership.

BioXconomy (BX): How do you think Europe could better capitalize on its scientific strengths?

Steve Yang (SY):Europe has exceptional scientific talent, but historically, there's been a gap in translating groundbreaking discoveries into commercial development. While funding has traditionally been stronger in the US, Europe can significantly improve its innovation output by streamlining the translation from basic research to market-ready products. This is precisely where WuXi AppTec's integrated contract research development and manufacturing organization (CRDMO) model creates tangible value.

A key reason for the success of the US biotech sector is the adoption of CRO, CDMO, and CMO services. By embracing structured scalability, early-stage engagement with integrated CRDMOs, effective tech transfer, and stronger pan-European collaborations, Europe can develop more sustainable, growth-oriented biotech companies rather than short-term projects.

BX: What advantages does a CRDMO provide?

SY:A CRDMO not only provides infrastructure and technical capabilities across the entire drug development cycle but also plays a key educational role: it supports academic spin-offs and early-stage companies in navigating regulatory frameworks, industrial quality standards, and scale-up processes. For example, a university spin-off developing a novel peptide therapy may lack experience in formulation or good manufacturing practice (GMP) production; by partnering with a CRDMO like WuXi AppTec, it gains both executional capacity and critical industry knowledge.

BX: Could you speak specifically about WuXi AppTec's capabilities and strategy in Europe?

SY:Europe represents our next major strategic growth frontier. WuXi AppTec already maintains operational sites in Munich, Germany, and Couvet, Switzerland […] Munich focuses on early-stage drug discovery and provides customized services in drug discovery, X-ray crystallography, protein supply, and biophysical analysis. Couvet specializes in drug product manufacturing and packaging, offering flexibility in late-stage clinical and commercial-scale production.

Yet this commitment extends beyond operational presence to integration in local ecosystems, including investments in sustainability, such as geothermal energy, solar power, and rainwater recycling at our Swiss site. Our European expansion also prioritizes empowering local management and fostering workforce development to ensure long-term, community-driven growth.

We proactively collaborate with European academic institutions, venture capital (VC) investors, and emerging biotech companies through ecosystem-building events and strategic partnerships. This active engagement ensures WuXi AppTec remains not merely a service provider, but rather a pivotal enabler of Europe's long-term biotech innovation and growth.

BX: You mentioned sustainability. What does a sustainable biotech ecosystem mean to you?

SY:A sustainable biotech ecosystem means having a robust framework where innovative research seamlessly progresses from discovery through commercial realization. It's about enabling biotech companies to scale effectively without large upfront investments, attracting sustained venture capital interest, and building diversified, long-term pipelines.

Equally important is the need to deepen collaboration between scientific hubs. Different regions have distinct strengths, Munich excels in early-stage venturing, Berlin in clinical research, and Heidelberg in fundamental science. Connecting these hubs through structured partnerships will create a more cohesive innovation landscape. This collaboration should also extend internationally, with clusters in the US and UK, offering exposure to best practices and new market opportunities.

A proven example is the Massachusetts biotech ecosystem, renowned for effectively integrating foundational research, capital, strategic investors, industry expertise, and scalable development capacities, providing a clear blueprint for Europe's potential success.

BX: We can’t ignore the financial side of things. How are VCs changing their approach to development partners, and what implications does this have?

SY:With biotech companies now often pursuing later-stage exits, VCs have heightened expectations regarding commercial readiness and accelerated product development. Investors look for clear, compliant, and efficient routes to market, as these directly influence valuations and exit potentials.

Small and emerging biotech firms, typically capital- and resource-constrained, benefit significantly by partnering with comprehensive CRDMOs.

This "flywheel" model, driven by consistent quality, speed, and cost-efficiency, ensures continuous innovation momentum, helping clients achieve higher valuations, attract investment, and ultimately reach markets faster and more reliably.

免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。